Discovering the Best Dose of Wegovy for Weight Loss

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no single best dose of Wegovy for weight loss — the Wegovy prescribing information defines more than one maintenance option, and which one applies to a given person is a prescriber's determination, not a number an article can supply. For weight reduction in adults, the label identifies a maintenance dosage of either 1.7 mg or 2.4 mg once weekly, with 2.4 mg designated as the recommended maintenance dosage, and it permits an increase to a maximum dosage of 7.2 mg once weekly for adult weight reduction. Those are the labeled options. The schedule that governs you is the one on your pharmacy label, and any change to it comes from the clinician who wrote the prescription.

What the Label Actually Defines

Wegovy injection is supplied in single-dose pens at 0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg, along with syringes and a multi-dose pen presentation. Most of those strengths exist to support a stepwise escalation over several months rather than as destinations. The label reserves the term maintenance dosage for the levels intended to be continued.

Those maintenance levels differ by indication, which is the part most dose comparisons miss. For cardiovascular risk reduction the label lists either 2.4 mg (recommended) or 1.7 mg once weekly. For weight reduction in adults it lists either 1.7 mg or 2.4 mg, with 2.4 mg recommended. For patients aged 12 and older with obesity it lists 2.4 mg (recommended) or 1.7 mg. For noncirrhotic MASH it lists 2.4 mg weekly, with a permitted reduction to 1.7 mg. The 7.2 mg maximum applies to adult weight reduction only.

Why an Escalation Period Exists

The stepwise increase is not about building efficacy slowly; it is about tolerability. Across the semaglutide and tirzepatide obesity trials, gastrointestinal adverse events were the most common events reported, most were mild to moderate, and they occurred primarily during dose escalation. Starting at a low dosage and increasing over months is the mechanism by which the label attempts to get people to a maintenance level they can stay on.

That reframes the question. The dose that produces the largest average result in a trial is not useful if it cannot be tolerated for a year. The label's escalation structure exists precisely because the practical ceiling is individual.

What the Higher Dose Was Tested Against

The 7.2 mg option is backed by a randomized trial rather than extrapolation. STEP UP was a phase 3b, randomized, double-blind, placebo- and active-controlled trial across 95 sites in 11 countries, enrolling 1,407 adults with a BMI of 30 kg/m² or greater and without diabetes, randomized 5:1:1 to once-weekly semaglutide 7.2 mg, 2.4 mg or placebo with a lifestyle intervention for 72 weeks. Mean baseline weight was 113.0 kg and mean BMI 39.9 kg/m².

Mean change in body weight was −18.7% with 7.2 mg versus −15.6% with 2.4 mg, an estimated treatment difference of −3.1%. The FDA approved the higher 7.2 mg dose, called Wegovy HD, on March 19, 2026, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related condition. A companion trial, STEP UP T2D, ran the same comparison in 512 adults with obesity and type 2 diabetes.

A Three-Point Difference Is Not a Reason by Itself

Reading STEP UP as "7.2 is better than 2.4" flattens what the trial showed. The estimated treatment difference of −3.1% is a group average, and the 2.4 mg arm already produced −15.6%. Whether an additional increment justifies a higher dosage depends on how far someone is from their clinical goal, how they tolerated the lower dosage, what their other conditions are, and what the prescriber is trying to achieve.

It also matters that the 7.2 mg maximum is labeled for adult weight reduction only. It is not part of the cardiovascular risk reduction indication, the adolescent indication or the MASH indication. A dosage is approved for a purpose, not in the abstract.

The Oral Form Is a Different Product Entirely

Wegovy is also available as tablets, approved December 22, 2025, with a maintenance strength of 25 mg. The tablet strengths — 1.5 mg, 4 mg, 9 mg and 25 mg — are not interchangeable with injection strengths in any way. Oral semaglutide has different bioavailability, and the milligram figures are not comparable across routes.

The tablets' labeled indications are also narrower than the injection's: cardiovascular risk reduction and weight reduction in adults with obesity or overweight with comorbidities. If you have read a dose figure somewhere and it does not match your pen, the route is the most likely explanation.

One Labeled Rule Applies to Everyone

The Wegovy label carries an explicit limitation of use: concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. That rules out the most common self-directed dose experiment — stacking products or adding a second agent to chase a faster result.

It is worth saying plainly that "finding your best dose" is not a self-service process. Dosage selection, timing of any increase, and what to do about a dose that is not tolerated are all clinical decisions, and they are made against your full medication list and history.

Compounded Semaglutide Has No Labeled Dose

Compounded semaglutide is not an FDA-approved finished product. The FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed, and they do not carry FDA-approved labeling — which means there is no approved maintenance dosage for them to reference. They are prepared by licensed pharmacies pursuant to prescriptions for individual patients.

Wegovy and Ozempic are the FDA-approved semaglutide brands, and a compounded preparation is not a generic version of either. Every dosage figure in this article comes from Wegovy's approved labeling or from the trials that supported it, and should be read as belonging to those products.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What is the maintenance dose of Wegovy for weight loss?

The Wegovy label identifies a maintenance dosage of either 1.7 mg or 2.4 mg once weekly for weight reduction in adults, with 2.4 mg designated as the recommended maintenance dosage. The label also permits an increase to a maximum of 7.2 mg once weekly for adult weight reduction. Which applies to you is determined by your prescriber, and the schedule that governs you is the one printed on your pharmacy label.

Is the 7.2 mg dose more effective than 2.4 mg?

In the STEP UP trial, 1,407 adults with obesity and without diabetes were randomized to semaglutide 7.2 mg, 2.4 mg or placebo for 72 weeks. Mean body weight change was −18.7% with 7.2 mg versus −15.6% with 2.4 mg, an estimated treatment difference of −3.1%. That is a group average, and the higher dosage is labeled for adult weight reduction only, not for the other Wegovy indications.

Why does Wegovy start at a low dose?

The escalation is about tolerability rather than efficacy. Across the semaglutide obesity trials, gastrointestinal adverse events were the most commonly reported events, were mostly mild to moderate, and occurred primarily during dose escalation. Increasing gradually is the label's mechanism for getting people to a maintenance level they can sustain. The specific timing for any individual comes from the prescriber and the pharmacy label.

Can I take Wegovy tablets and the injection together?

No. The Wegovy label carries an explicit limitation of use stating that concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. The tablet strengths of 1.5, 4, 9 and 25 mg are also not interchangeable with injection strengths, because oral and injectable semaglutide differ in bioavailability.

Does compounded semaglutide have an approved dose?

No. Compounded semaglutide is not an FDA-approved finished product and does not carry FDA-approved labeling, so there is no approved maintenance dosage attached to it. The FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. They are prepared by licensed pharmacies pursuant to prescriptions for individual patients, and dosing is directed by the prescriber.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.